文献速递血栓与止血

静脉血栓栓塞预防试验中临床事件裁定委员会裁定的可重复性

Reproducibility of clinical events adjudications in a trial of venous thromboembolism prevention.
PubMed 文献 · J Thromb Haemost · 2017-03-01

PREVENU试验纳入15 351例住院内科患者,随机抽取179例已裁定事件盲法重新提交临床事件委员会(CEC)裁定。总体不一致率为10.1%(95%CI 6.5-15.3%),复合主要终点Kappa=0.73(95%CI 0.61-0.85);非致死性VTE和出血事件一致性良好,VTE相关死亡一致性不足。

要点

  • CEC裁定总体不一致率10.1%(95%CI 6.5-15.3%),复合主要终点Kappa=0.73(95%CI 0.61-0.85)。
  • 非致死性VTE事件Kappa=1,所有VTE事件Kappa=0.58(95%CI 0.34-0.82),所有致死事件Kappa=0.60(95%CI 0.40-0.81)。
  • 不明原因猝死(可能致死性PE)占不一致裁定的9/18(50%)。

核心结论

  • CEC裁定对非致死性VTE和出血事件的可重复性为良好或很好,但对VTE相关死亡的可重复性不足,需要更精确且广泛接受的定义。

研究设计与样本

  • PREVENU试验为多中心静脉血栓栓塞预防试验,纳入15 351例住院内科患者。
  • 主要终点为3个月内有症状VTE、大出血或不明原因猝死(解释为可能的致死性肺栓塞[PE])的复合终点。
  • CEC由1名主席和4对裁定者组成;从2970例已裁定临床事件中随机抽取179例事件(121例死亡、40例出血事件、18例VTE事件)盲法重新提交CEC裁定。
  • 计算Kappa值及其95%置信区间(CI)以衡量裁定一致性。

主要发现

  • 总体18/179例裁定不一致(10.1%,95%CI 6.5-15.3%)。
  • PREVENU复合主要终点一致性良好(Kappa=0.73,95%CI 0.61-0.85)。
  • 非致死性VTE事件一致性很好(Kappa=1,95%CI不适用)。
  • 所有(致死和非致死)VTE事件一致性中等(Kappa=0.58,95%CI 0.34-0.82)。
  • 致死和非致死性大出血事件一致性良好(Kappa=0.71,95%CI 0.55-0.88);所有致死事件一致性中等(Kappa=0.60,95%CI 0.40-0.81);不明原因猝死解释为可能致死性PE占不一致裁定的9/18(50%)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Essentials The reproducibility of Clinical Events Committee (CEC) adjudications is almost unexplored. A random selection of events from a venous thromboembolism trial was blindly re-adjudicated. 'Unexplained sudden deaths' (possible fatal embolism) explained most discordant adjudications. A precise definition for CEC adjudication of this type of events is needed and proposed. SUMMARY: Background When clinical trials use clinical endpoints, establishing independent Clinical Events Committees (CECs) is recommended to homogenize the interpretation of investigators' data. However, the reproducibility of CEC adjudications is almost unexplored. Objectives To assess the reproducibility of CEC adjudications in a trial of venous thromboembolism (VTE) prevention. Methods The PREVENU trial, a multicenter trial of VTE prevention, included 15 351 hospitalized medical patients. The primary endpoint was the composite of symptomatic VTE, major bleeding or unexplained sudden death (interpreted as possible fatal pulmonary embolism [PE]) at 3 months. The CEC comprised a chairman and four pairs of adjudicators. Of 2970 adjudicated clinical events, a random selection of 179 events (121 deaths, 40 bleeding events, and 18 VTE events) was blindly resubmitted to the CEC. Kappa values and their 95% confidence intervals (CIs) were calculated to measure adjudication agreement. Results Overall, 18 of 179 (10.1%, 95% CI 6.5-15.3%) adjudications proved discordant. Agreement for the PREVENU composite primary endpoint was good (kappa = 0.73, 95% CI 0.61-0.85). When analyzed separately, agreements were very good for non-fatal VTE events (1, 95% CI not applicable), moderate for all (fatal and non-fatal) VTE events (0.58, 95% CI 0.34-0.82), good for fatal and non-fatal major bleeding events (0.71, 95% CI 0.55-0.88), and moderate for all fatal events (0.60, 95% CI 0.40-0.81). Unexplained sudden death interpreted as possible fatal PE was responsible for nine of 18 (50%) discordant adjudications. Conclusion The reproducibility of CEC adjudications was good or very good for non-fatal VTE and bleeding events, but insufficient for VTE-related deaths, for which more precise and widely accepted definitions are needed.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Girard P, Penaloza A, Parent F, et al. Reproducibility of clinical events adjudications in a trial of venous thromboembolism prevention. J Thromb Haemost. 2017. PMID: 28092428. doi:10.1111/jth.13626

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。